Diana Brainard, Gilead head of virology
'Are you guys out of virology?': Not hardly, says Gilead execs, as they buy a late-stage drug company for $1.7B
Gilead has turned the spotlight in M&A and BD to cancer since Dan O’Day took the top spot at the company. But today …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
